EGFR and pancreatic neoplasm: In a previous study, the downstream signaling of EGFR was inhibited in pancreatic cancer cells by gemcitabine and cetuximab combination treatment (23), which was not observed in the HNSCC cell lines used in our study (Fig. 4).